Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Metallo-beta-lactamase domain-containing protein 2 (MBLAC2) is a human enzyme that belongs to the metallo-beta-lactamase (MBL) superfamily, sharing a conserved αββα-fold structure and a metal-binding catalytic site, typically coordinating zinc ions. MBLAC2 is a zinc-dependent hydrolase with acyl-CoA thioesterase activity, meaning it hydrolyzes long-chain fatty acyl-CoA substrates, contributing to fatty acid metabolic processes and lipid regulation in the cell. Uniquely, MBLAC2 is S-palmitoylated and found on cellular membranes, interacting with specific acyltransferases such as zDHHC20 and possibly influencing substrate protein palmitoylation—but its exact physiological and disease relevance remains to be fully established. MBLAC2 is detected in the endoplasmic reticulum and plasma membrane and may be functionally linked to the regulation of lipid metabolism. No approved drugs currently target MBLAC2, and no major safety concerns have been linked to inhibition or modulation of this enzyme.
No drugs target MBLAC2 in clinical use; mechanism would be expected hydrolase inhibition if developed
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Metallo-beta-lactamase domain-containing protein 2 (MBLAC2).